VIP Peptide Research

Interest in VIP peptide research has increased across immunology, gastrointestinal biology, pulmonary medicine and neuroscience. Common searches now include VIP peptide results, VIP peptide UK, vasoactive intestinal peptide research, UK peptides and peptides UK.

VIP is quite different from many synthetic research peptides. It is a naturally occurring signalling molecule found throughout the nervous system, digestive tract, lungs and immune system. It has also been investigated pharmaceutically under the name aviptadil, including in human studies involving pulmonary hypertension and acute respiratory distress syndrome.

However, VIP’s wide range of biological functions does not mean that every proposed application is clinically established. Much of the most interesting evidence still comes from cell cultures and animal models, while human pulmonary and immune studies have produced mixed or preliminary findings.

At Elvian Labs, we believe it is important to distinguish established physiology from experimental therapeutic claims. This article reviews what VIP is, how it works and what laboratory, rodent and human research currently shows.

What Is VIP?

Vasoactive intestinal peptide, commonly abbreviated to VIP, is a naturally occurring peptide composed of 28 amino acids.

It was originally isolated from intestinal tissue after researchers identified a substance capable of producing powerful vasodilation. Despite its name, VIP is not confined to the intestine.

It is widely distributed throughout:

• The enteric nervous system
• The central and peripheral nervous systems
• The lungs and airways
• The pancreas
• The cardiovascular system
• The reproductive system
• Multiple populations of immune cells

VIP functions both as a neuropeptide and as an immune-regulating signalling molecule. Its effects vary depending on which tissue releases it, which receptor is activated and the physiological context in which that signalling occurs.

VIP 10 mg 

Is VIP the Same as Aviptadil?

Aviptadil is the pharmaceutical name commonly used for synthetic human vasoactive intestinal peptide.

The amino-acid sequence is intended to reproduce naturally occurring human VIP. However, aviptadil formulations used in clinical research are controlled pharmaceutical preparations and should not automatically be considered equivalent to every product labelled as a VIP research peptide.

Clinical studies involving aviptadil have used routes including:

• Intravenous infusion
• Inhalation
• Intranasal administration in experimental settings
• Other specialised pharmaceutical delivery systems

The formulation and route are particularly important because natural VIP is broken down rapidly in circulation.

How Does VIP Work?

VIP produces most of its biological effects through two G-protein-coupled receptors:

• VPAC1
• VPAC2

VIP can bind to both receptors. These receptors are distributed differently throughout the body and can produce distinct effects depending on the cell type involved.

Receptor activation generally stimulates the enzyme adenylyl cyclase, increasing intracellular cyclic adenosine monophosphate, or cAMP. This signalling pathway can influence smooth-muscle relaxation, secretion, immune-cell activity, gene expression and cellular survival.

Structural research has now mapped how VIP interacts with the VPAC1 receptor, helping researchers understand the molecular basis of receptor activation and peptide selectivity. (PubMed)

VIP 5 mg 

VPAC1 and VPAC2 Receptors

Although both receptors respond to VIP, their distribution and biological roles are not identical.

VPAC1 is expressed in tissues including the gastrointestinal tract, lungs and several immune-cell populations. It is frequently associated with smooth-muscle regulation, secretion and anti-inflammatory immune signalling.

VPAC2 is found in the central nervous system, pancreas, smooth muscle and activated immune cells. It has been investigated in relation to circadian rhythms, insulin secretion, airway biology and T-cell function.

Human immune-cell research has shown that VPAC1 and VPAC2 expression changes as T cells become activated. This suggests that VIP’s effect on immunity may depend partly on the activation state of the cell rather than following one fixed pattern. (PubMed)

Why Is VIP Biologically Complex?

VIP is sometimes described simply as an anti-inflammatory or vasodilating peptide. Both descriptions are valid, but neither captures its full biology.

Depending on the tissue and receptor involved, VIP can influence:

• Blood-vessel dilation
• Intestinal secretion
• Smooth-muscle relaxation
• Airway tone
• Immune tolerance
• Cytokine production
• T-cell differentiation
• Insulin secretion
• Circadian signalling
• Neuroprotection
• Epithelial-barrier function
• Cellular growth and differentiation

A biological effect that is useful in one setting may be undesirable in another. For example, vasodilation could potentially support blood flow but may also contribute to flushing or reduced blood pressure.

Similarly, reducing an excessive immune response may be valuable during inflammatory injury, but broad immune suppression could theoretically be undesirable during certain infections.

VIP and the Digestive System

VIP was first identified in intestinal tissue, and its role within the digestive system remains one of its best-established physiological functions.

VIP is released by neurons within the enteric nervous system and contributes to:

• Relaxation of gastrointestinal smooth muscle
• Increased intestinal water and electrolyte secretion
• Mucosal blood flow
• Pancreatic and biliary secretion
• Communication between intestinal nerves and immune cells
• Maintenance of aspects of the epithelial barrier

Recent laboratory research found that VIP directly influenced intestinal epithelial progenitor cells and promoted differentiation toward secretory cell populations. This suggests that neuronal VIP signalling may participate not only in motility and secretion, but also in maintaining the cellular composition of the intestinal lining. (PubMed)

Intestinal-Barrier Research

The intestinal epithelium forms a selective barrier between the contents of the digestive tract and the circulation.

Animal research has investigated whether VIP helps regulate the proteins that control permeability between epithelial cells. In a mouse model of intestinal inflammation, VIP was reported to reduce disruption of the epithelial barrier and alter tight-junction regulation. (PubMed)

This has contributed to interest in VIP peptide research involving inflammatory bowel disease and other conditions associated with increased intestinal permeability.

However, VIP’s effects on intestinal secretion mean that its gastrointestinal biology is not uniformly protective. Excessive VIP signalling can produce profound watery diarrhoea, as seen in rare VIP-secreting tumours.

It would therefore be inaccurate to describe VIP simply as a gut-healing peptide.

VIP and Immune Regulation

VIP is produced not only by neurons but also by certain immune cells. It participates in communication between the nervous and immune systems.

Laboratory research suggests that VIP can reduce the production of several inflammatory mediators while encouraging regulatory or tolerance-associated immune responses.

Potentially affected pathways include:

• Tumour necrosis factor alpha
• Interleukin-6
• Interleukin-12
• Chemokine signalling
• Nuclear factor kappa B
• Dendritic-cell maturation
• Regulatory T-cell development
• T-helper-cell differentiation

VIP is therefore more accurately described as an immunomodulatory neuropeptide than as a simple immune suppressant.

Dendritic Cells and Immune Tolerance

Dendritic cells detect antigens and help determine the type of adaptive immune response that follows.

Human cell-culture research found that the presence of VIP during dendritic-cell development produced a more tolerogenic phenotype. These cells generated more interleukin-10 and were able to promote regulatory CD4 and CD8 T-cell populations from naïve T cells. (PubMed)

This work helped establish a biological rationale for investigating VIP in:

• Autoimmune disease
• Transplantation
• Graft-versus-host disease
• Chronic inflammatory disorders
• Conditions involving inappropriate immune activation

However, laboratory generation of regulatory immune cells does not establish that systemic VIP administration safely produces the same outcome in humans.

T-Cell Research

VIP and its receptors are involved in the regulation of T-cell behaviour.

Animal studies involving altered VPAC2 expression have demonstrated shifts between different types of immune responses. Mice overexpressing VPAC2 in CD4 T cells showed greater features of immediate-type hypersensitivity, whereas VPAC2-deficient animals displayed a different immune profile. (PubMed)

These findings show why VIP cannot be characterised as uniformly anti-inflammatory in every context. The outcome depends on receptor expression, immune-cell type and the particular immune challenge.

VIP may reduce selected inflammatory pathways while simultaneously favouring other immune responses.

Autoimmune-Disease Research

VIP has produced encouraging findings in multiple experimental autoimmune models.

Preclinical research has investigated it in models of:

• Rheumatoid arthritis
• Inflammatory bowel disease
• Multiple sclerosis-like disease
• Type 1 diabetes
• Sjögren’s syndrome
• Autoimmune uveitis
• Graft-versus-host disease

Across some of these models, VIP reduced inflammatory-cell migration, altered cytokine production and encouraged regulatory immune responses.

Reviews have described VIP as an endogenous mechanism through which the body may promote immune tolerance after inflammation or exposure to foreign antigens. (PubMed)

Nevertheless, results from induced autoimmune disease in rodents cannot establish clinical efficacy in people with complex, long-standing autoimmune conditions.

Chemokines and Immune-Cell Migration

Inflammatory cells must move from the bloodstream into tissues before many immune reactions can occur.

Experimental research has shown that VIP can reduce chemokine-receptor signalling and inhibit the migration of selected immune-cell populations. In a mouse model of delayed hypersensitivity, this was associated with reduced inflammatory recruitment. (PubMed)

This mechanism may partly explain the anti-inflammatory VIP peptide results observed in certain animal models.

It also highlights that VIP can influence where immune cells travel, not merely how many cytokines they produce.

Pulmonary and Airway Research

VIP is widely distributed within the respiratory system.

It can relax airway and vascular smooth muscle and has been investigated for potential effects on:

• Pulmonary blood flow
• Bronchial tone
• Alveolar function
• Inflammatory signalling
• Pulmonary hypertension
• Acute lung injury
• Acute respiratory distress syndrome

These actions led to the pharmaceutical development of aviptadil for serious pulmonary conditions.

However, VIP’s rapid degradation and systemic vasodilating effects have made pharmaceutical development difficult.

VIP and Pulmonary Hypertension

Pulmonary arterial hypertension involves increased resistance within the blood vessels supplying the lungs.

Because VIP is a potent pulmonary vasodilator and may influence vascular remodelling, aviptadil has been investigated as a potential treatment. It has received orphan-drug designation for pulmonary arterial hypertension and acute respiratory distress syndrome, but orphan designation is not the same as regulatory approval. (PubMed)

Small early studies have reported improvements in selected haemodynamic or functional measurements, particularly with inhaled delivery. However, the overall evidence has not established aviptadil as a routine treatment for pulmonary hypertension.

Larger controlled studies and optimised formulations remain necessary.

Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome, or ARDS, involves severe inflammation and damage to the barrier between the lung’s air sacs and blood vessels.

VIP became a candidate for ARDS research because it may:

• Dilate pulmonary blood vessels
• Reduce inflammatory signalling
• Protect alveolar epithelial cells
• Influence surfactant production
• Support the alveolar-capillary barrier

Aviptadil was studied extensively during the COVID-19 pandemic, when severe viral pneumonia frequently led to ARDS.

Aviptadil and COVID-19 Research

Early case series and uncontrolled reports generated considerable interest in aviptadil for critically ill patients with COVID-19.

However, early observations cannot reliably separate a treatment effect from differences in disease severity, intensive-care practice or natural recovery.

Subsequent controlled trials did not establish a clear universal mortality benefit. Some analyses suggested possible improvements in selected secondary outcomes or subgroups, but the evidence was not sufficiently consistent to make aviptadil a standard COVID-19 treatment.

The development programme illustrates an important principle: a plausible biological mechanism and encouraging emergency-use observations do not guarantee success in larger randomised trials.

Aviptadil continues to be discussed in ARDS research, including non-COVID causes, but published clinical experience remains preliminary. (PubMed)

Experimental Lung-Development Research

Animal research continues to explore VIP in less familiar pulmonary settings.

A 2025 rat study examined aviptadil in a model of congenital diaphragmatic hernia-associated pulmonary hypoplasia. Treatment partially restored VIP expression and was associated with reduced vascular remodelling and alveolar abnormalities. (PubMed)

This is an interesting preclinical finding, but it relates to a specialised developmental model in rats and does not establish efficacy in human infants.

VIP and Neuroprotection

VIP is widely distributed within the brain and can influence neurons, astrocytes and microglia.

Laboratory studies have investigated potential neuroprotective effects involving:

• Oxidative stress
• Excitotoxicity
• Amyloid-beta toxicity
• Dopaminergic-neuron injury
• Microglial activation
• Neurotrophic signalling

In neuronal cultures, VIP reduced toxicity produced by several experimental neurotoxins and amyloid-beta. Some of these effects appeared to occur indirectly through glial release of highly potent neuroprotective proteins. (PubMed)

These findings helped inspire research into shorter neuroprotective fragments derived from proteins regulated by VIP, including ADNP-related peptides.

However, protective effects in cultured neurons do not demonstrate that unmodified VIP reaches relevant brain regions in sufficient concentrations after peripheral administration.

Microglia and Neuroinflammation

Microglia are resident immune cells within the central nervous system.

When activated excessively, they can release inflammatory mediators that contribute to neuronal injury. Cell-culture research found that VIP reduced microglia-mediated neurotoxicity and decreased the release of selected inflammatory factors. (PubMed)

This has contributed to research interest involving neurodegeneration, traumatic injury and inflammatory neurological disease.

The major translational challenge is drug delivery. VIP is rapidly degraded and does not necessarily reach the brain efficiently after conventional peripheral administration.

VIP and Circadian Biology

VIP is an important signalling molecule within the suprachiasmatic nucleus, the brain region that coordinates circadian rhythms.

VIP-producing neurons help synchronise the internal clocks of neighbouring cells. Animal models with disrupted VIP or VPAC2 signalling can show fragmented or weakened daily rhythms.

This has made VIP relevant to research involving:

• Sleep-wake timing
• Circadian synchronisation
• Light responses
• Hormonal rhythms
• Metabolic timing

However, the fact that endogenous VIP is essential for circadian organisation does not establish that externally administered VIP improves sleep.

The timing, location and natural pulsatility of signalling within the suprachiasmatic nucleus are difficult to reproduce pharmacologically.

VIP and Glucose Regulation

VIP is present within pancreatic nerves and can influence insulin and glucagon secretion.

Laboratory and rodent research has shown that VPAC2-receptor activation can enhance glucose-stimulated insulin secretion from pancreatic beta cells through effects on intracellular signalling and ion channels. (PubMed)

This has encouraged development of receptor-selective compounds for metabolic research.

However, VIP itself is not a straightforward glucose-lowering peptide. It can influence several hormones and may produce different effects depending on glucose concentration, receptor distribution and route of administration.

Human metabolic benefits have not been established through robust clinical trials of generic VIP.

Cardiovascular and Vasodilatory Effects

The word “vasoactive” reflects VIP’s ability to relax vascular smooth muscle.

VIP can dilate blood vessels through cAMP-dependent mechanisms and interactions with endothelial signalling. Research has identified VPAC receptors within cerebral arteries and shown that they participate in VIP-induced vasodilation. (PubMed)

Potential physiological effects can include:

• Reduced vascular resistance
• Increased local blood flow
• Facial flushing
• Headache
• Increased heart rate
• Reduced blood pressure

These effects may be relevant to pulmonary research but also create safety and tolerability limitations.

VIP should therefore not be portrayed as a benign wellness peptide simply because it occurs naturally in the body.

Liver-Injury Research

VIP has also been investigated in models of organ injury outside the lungs and nervous system.

In a mouse model of liver ischaemia followed by reperfusion, VIP administration reduced inflammatory injury and was associated with protective immune and tissue-repair responses. Endogenous VIP expression also increased during the recovery phase. (PubMed)

This suggests that VIP may participate in natural responses to acute tissue damage.

However, an experimental liver ischaemia model is very different from chronic fatty-liver disease, viral hepatitis or human liver failure. Results should not be generalised beyond the model studied.

Why Is VIP Difficult to Develop as a Medicine?

VIP has compelling biological activity, but it also has several pharmacological limitations.

The native peptide is rapidly broken down by enzymes, giving it a very short duration in circulation. This can make it difficult to maintain a useful concentration without continuous infusion or specialised delivery.

Other development challenges include:

• Systemic vasodilation
• Reduced blood pressure
• Increased heart rate
• Headache and flushing
• Gastrointestinal secretion
• Limited tissue targeting
• Potential loss of receptor selectivity
• Difficulty delivering sufficient peptide to the brain

Researchers have therefore investigated:

• Inhaled formulations
• Liposomal delivery systems
• Modified VIP analogues
• Receptor-selective agonists
• Nanoparticle carriers
• More stable peptide sequences

A longer-lasting analogue may not perfectly reproduce natural VIP biology, however, because prolonged receptor activation can produce different effects from short physiological pulses.

Injectable VIP Research

Intravenous or injectable aviptadil has been used in some pulmonary and intensive-care studies.

Systemic administration produces measurable exposure but also increases the likelihood of whole-body vasodilatory effects. A formulation intended to reach lung tissue may therefore require careful control of concentration and infusion rate.

Results obtained through continuous intravenous administration cannot automatically be transferred to intermittent subcutaneous administration or research-grade injectable VIP.

There is currently no robust evidence establishing a general injectable VIP protocol for immune support, gut health, cognitive enhancement or longevity.

Inhaled VIP Research

Inhaled administration has been investigated as a way to target the respiratory system while reducing systemic exposure.

This route has been studied in pulmonary hypertension, sarcoidosis and severe lung injury. Local delivery may theoretically expose lung tissue to higher concentrations while limiting reductions in systemic blood pressure.

However, inhaled delivery still requires pharmaceutical formulation, device validation and controlled particle characteristics. It cannot be assumed that any nebulised VIP preparation will reproduce the exposure achieved in a clinical study.

Intranasal VIP Research

Intranasal VIP is sometimes discussed in connection with neurological, inflammatory or chronic multisystem conditions.

The proposed rationale is that nasal administration might provide access to neural pathways while avoiding some digestive or systemic degradation.

However, evidence confirming reliable delivery of intact VIP into the human brain remains limited. Human data supporting intranasal VIP for cognitive enhancement, sleep, chronic fatigue, mould-related illness or general neuroinflammation are not robust.

Claims in these areas often extend well beyond controlled clinical evidence.

Understanding “VIP Peptide Results”

Searches for VIP peptide results, VIP experience or VIP peptide before and after may lead to anecdotal reports involving:

• Easier breathing
• Reduced inflammation
• Improved digestion
• Changes in sleep
• Increased mental clarity
• Flushing or light-headedness
• Changes in blood pressure

These reports cannot establish that VIP caused the observed effect.

Possible confounding factors include:

• Natural variation in symptoms
• Concurrent medication
• Changes in diet or sleep
• Placebo effects
• Differences in route and formulation
• Rapid peptide degradation
• Inaccurate concentration
• Product misidentification
• Variation in receptor expression

The strongest scientific evidence demonstrates that VIP is a biologically important neuroimmune peptide. Evidence supporting many of the applications discussed online remains preliminary or absent.

Is VIP an Approved Medicine?

Synthetic VIP has been investigated pharmaceutically as aviptadil, and certain programmes have received orphan-drug designation or authorisation to enter clinical trials.

This does not mean that VIP is broadly approved for pulmonary disease, immune disorders, neurological conditions or general wellness.

Orphan-drug designation is intended to support development for rare or serious conditions. It does not establish effectiveness and is not equivalent to marketing authorisation.

The regulatory status of any particular formulation also depends on jurisdiction, indication and manufacturer.

Pharmaceutical Aviptadil Versus Research-Grade VIP

Clinical research generally uses a defined pharmaceutical formulation with controlled identity, sterility and stability.

A product sold as research-grade VIP may differ in:

• Peptide content
• Amino-acid sequence confirmation
• Purity
• Counter-ion content
• Water content
• Sterility
• Endotoxin level
• Aggregation
• Stability after reconstitution
• Storage history

This matters particularly for VIP because it is an unstable peptide and is active at relatively low concentrations.

Published clinical evidence involving a pharmaceutical aviptadil formulation should not automatically be attributed to all products labelled VIP.

VIP UK and Research Classification

Searches for VIP peptide UK, UK peptides and peptides UK often lead to compounds supplied strictly for laboratory investigation.

VIP is a naturally occurring human peptide, but a research-grade preparation is not automatically a licensed medicine. Its physiological presence in the body does not demonstrate that externally administered material is safe or effective for an unapproved purpose.

Research classification is particularly relevant because evidence differs substantially across:

• Natural endogenous VIP
• Pharmaceutical aviptadil
• Inhaled preparations
• Intravenous formulations
• Intranasal products
• Modified analogues
• Generic research-grade material

These categories should not be treated as interchangeable.

Current State of the Evidence

Among compounds discussed within the UK peptides research community, VIP has one of the broadest biological profiles.

It has established physiological roles in intestinal signalling, smooth-muscle relaxation, vascular regulation, circadian communication and neuroimmune function. Laboratory and animal studies provide substantial evidence that VIP can influence dendritic cells, T-cell differentiation, inflammatory signalling, epithelial barriers and cellular protection.

Human pharmaceutical research has focused heavily on pulmonary conditions through aviptadil. Although some studies and case series have reported encouraging findings, controlled evidence has not established VIP as a routine treatment for ARDS, pulmonary hypertension, autoimmune disease or neurological illness.

Its short half-life, systemic vasodilatory effects and lack of tissue selectivity remain important barriers to clinical development.

The most accurate interpretation of current VIP peptide research is that VIP is a highly active endogenous neuroimmune peptide with credible mechanistic and preclinical evidence, but with limited and condition-specific human therapeutic evidence.

It should not be portrayed as a proven general treatment for inflammation, gastrointestinal dysfunction, cognitive decline, respiratory illness or longevity.

This article is intended for educational purposes only and summarises published scientific and regulatory research. It should not be interpreted as medical advice, a recommendation for human use or evidence of clinical efficacy for any unapproved application.

The next logical companion article would be VIP versus PACAP, since the two peptides share VPAC receptors but have meaningfully different receptor selectivity and neurological biology.